- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Alternative Capital and Credit Funds
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology and Emerging Companies
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Insurance Coverage and Recovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- Careers
- News & Insights
- About
- Languages
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Alternative Capital and Credit Funds
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Investment Funds and Asset Management
- Leveraged Finance
- Mergers and Acquisitions
- Middle East and Islamic Finance and Investment
- Private Equity
- Real Estate
- Securitization
- Tax
- Technology and Emerging Companies
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Insurance Coverage and Recovery
- Intellectual Property, Patent, Trademark and Copyright Litigation
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
Capabilities
Our Securities Enforcement and Regulation group advises leading financial institutions, regulated entities and public companies, boards of directors and audit committees, and individual senior executives, officers, and directors in all types of securities law enforcement matters. These representations often remain non-public due to successful resolution without any action against our clients.
Our team includes the only person in history to have served as both Director of Enforcement and General Counsel of the SEC, a former Director of the SEC’s Northeast Regional Office, a former Assistant Director in the SEC’s Enforcement Division, a former Assistant Attorney General in charge of DOJ’s Criminal Division, a former U.S. Attorney who co-chaired the Securities and Commodities Fraud Working Group which includes the DOJ, Federal Bureau of Investigation, Securities and Exchange Commission, Commodity Futures Trading Commission, Financial Industry Regulatory Authority and other agencies, and a former Chief of the Securities and Commodities Fraud Task Force in the Southern District of New York’s U.S. Attorney’s Office, as well as other state and federal prosecutors, and experienced SEC enforcement practitioners focused on only securities matters. We regularly and successfully appear before the SEC, DOJ, CFTC, FINRA, PCAOB, the U.K FCA and other international authorities and state regulators.
We have the experience to guide you through the investigatory process, the credibility to advocate effectively for you before the enforcement authorities, and the judgment to help you achieve the best possible outcome in a variety of high-stakes matters.
Entities we serve:
- Public and Private Companies
- Boards and Board Committees
- Financial Institutions
- Investment Advisers and Private Funds
- Broker-dealers
- Credit Rating Agencies
- Private Equity and Venture Capital Funds
- Accounting Firms
- Law Firms
- Exchanges and Self-Regulatory Organizations
- Commodity Market Participants
- Municipalities and other Government Entities
Individuals we serve:
- Auditors
- Lawyers
- Directors and Officers
- Securities and Commodities Industry Professionals
- Other Professionals
Specialty matters:
- Auditor and Professional Liability
- Corporate Accounting and Disclosure
- Corporate Governance
- FCPA
- Asset Management
- Insider Trading and Tipping
- Complex Financial Products
Work for which we are recognized:
- Board Investigations
- Corporate Governance Counseling
- Compliance Counseling
- Cross-border Investigations
- Due Diligence
- Government Investigations
- Internal Investigations
- Litigation against the Government
- Regulatory Examination Counseling
Agencies/Organizations we appear before:
- Securities and Exchange Commission - SEC (we’ve appeared before all 12 field offices and specialized units)
- Department of Justice – DOJ (we’ve appeared before 73 of the 93 U.S. Attorney’s Offices)
- Financial Industry Regulatory Authority – FINRA
- Commodities Futures Trading Commission - CFTC
- Internal Revenue Service – IRS
- Food and Drug Administration – FDA
- Office of the Comptroller of Currency – OCC
- Public Company Accounting Oversight Board – PCAOB
- The Federal Reserve
- State Attorneys General
- UK Financial Conduct Authority - FCA
- Hong Kong Securities and Futures Commission
- Swiss Financial Market Supervisory Authority
- German BaFin
- Brazilian Federal Prosecution Offices
- Transport Canada
- World Bank
- NYS Department of Financial Services - DFS
Related Lawyers
Dixie Johnson and Carmen Lawrence Named to List of Top 40 Securities Enforcement Lawyers in the U.S.
Insights
Article · Source: New York Law Journal
November 6, 2019
Privilege Considerations in Special Board Committee Representations
Client Alert
October 31, 2019
Regulation Best Interest: Updates and Developments
Article · Source: Law360
October 30, 2019
An Internal Investigation Playbook For Energy Cos.: Part 3
Close
Recognition
"White Collar Practice Group of the Year"
Law360, 2010 and 2016
Recognized for Excellence For Securities and Financial Services Regulations
Chambers USA
Dixie Johnson ranked Band 1 for Securities Regulation
Chambers USA, 2017
Listed on annual list of world's top 30 firms for investigations
Global Investigations Review
Carmen Lawrence is "regularly representing clients in high stakes regulatory matters."
Chambers
"Dixie Johnson enjoys a 'long and excellent reputation' among market observers"
Chambers
"An impressed client describes the firm's lawyers as "top notch"
Chambers
"Dixie Johnson wins praise across the board for her "terrific" relationship with the SEC"
Chambers
Carmen Lawrence praised "for her 'outstanding' ability"
Chambers
"Clients speak to the 'practical nature of the team's advice."
Chambers
"They have a really thorough and expert understanding of the law."
Chambers
Recognized for being "straight-shooters and working collaboratively with other firms"
Chambers
News
Recognition
January 30, 2020
Dixie Johnson Elected Vice Chair of the Securities Regulation Institute
In the News · Source: The National Law Journal and Daily Report
In the News · Source: The Pink Sheet
December 14, 2019
Alec Koch explains if Sarepta Therapeutics needed to tell investors about its Vyondys 53 dispute resolution request